These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9477479)

  • 1. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
    Jiménez-Cabello L; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Illescas-Amo M; Benavides J; Moreno S; Marín-López A; Nogales A; Ortego J
    Front Immunol; 2024; 15():1440407. PubMed ID: 39072326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered multi-component virus-like particles as veterinary vaccines.
    Pearson LD; Roy P
    Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():381-9. PubMed ID: 8270267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topography and immunogenicity of bluetongue virus VP7 epitopes.
    Wang LF; Hyatt AD; Whiteley PL; Andrew M; Li JK; Eaton BT
    Arch Virol; 1996; 141(1):111-23. PubMed ID: 8629938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.
    Bouet-Cararo C; Contreras V; Caruso A; Top S; Szelechowski M; Bergeron C; Viarouge C; Desprat A; Relmy A; Guibert JM; Dubois E; Thiery R; Bréard E; Bertagnoli S; Richardson J; Foucras G; Meyer G; Schwartz-Cornil I; Zientara S; Klonjkowski B
    PLoS One; 2014; 9(11):e111605. PubMed ID: 25364822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus.
    Andrew M; Whiteley P; Janardhana V; Lobato Z; Gould A; Coupar B
    Vet Immunol Immunopathol; 1995 Aug; 47(3-4):311-22. PubMed ID: 8571549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant virus vaccine for bluetongue disease in sheep.
    Roy P; Urakawa T; Van Dijk AA; Erasmus BJ
    J Virol; 1990 May; 64(5):1998-2003. PubMed ID: 2157868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.
    Moreno S; Calvo-Pinilla E; Devignot S; Weber F; Ortego J; Brun A
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008942. PubMed ID: 33275608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
    Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
    PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Ortego J
    Methods Mol Biol; 2016; 1349():137-50. PubMed ID: 26458834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
    Jabbar TK; Calvo-Pinilla E; Mateos F; Gubbins S; Bin-Tarif A; Bachanek-Bankowska K; Alpar O; Ortego J; Takamatsu HH; Mertens PP; Castillo-Olivares J
    PLoS One; 2013; 8(4):e60574. PubMed ID: 23593251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.